
Join 900 US CEOs protest against Ukraine invasion
As Russia continues its unprovoked war on Ukraine, the U.S. life sciences community is united in its total rejection of the criminal actions taken by...

Catalent swallows VMIC Ltd
The biologics development and manufacturing facility taken over from Vaccine Manufacturing and Innovation Centre UK Ltd. is locaterd n to the south...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Meletios Therapeutics licences antiviral patent
Meletios has signed an exclusive license agreement with Institut Pasteur to commercialise Defective Viral Genomes (DVG). DVGs are truncated or...


mRNA for Africa
The plant is expected to have the capacity to fill and package 500 million doses annually. German competitor BioNTech SE has also announced plans to...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...